RSRC2 and esophageal cancer: The results showed that the expression of RSRC2 in cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal cancer (ESCA), head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and stomach adenocarcinoma (STAD) was significantly higher than that in the corresponding normal tissues (Figure 1A).